Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4102525 | 0.98 | RYR2 (0.97) | RYR2KCNH2 | |
| Bromide SCHEMBL31153304 | 0.98 | RYR2 (0.97) | RYR2KCNH2 | |
| SCHEMBL17892741 | 0.91 | RYR2 (0.83) | RYR2KCNH2 | |
| SCHEMBL14691719 | 0.87 | RYR2 (0.77) | RYR2KCNH2 | |
| SCHEMBL17892759 | 0.84 | RYR2 (0.73) | RYR2KCNH2 | |
| SCHEMBL7999750 | 0.80 | RYR2 (0.67) | RYR2KCNH2 | |
| Bromide SCHEMBL3425744 | 0.79 | RYR2 (0.65) | RYR2KCNH2 | |
| SCHEMBL17892756 | 0.78 | RYR2 (0.64) | RYR2KCNH2 | |
| SCHEMBL2600211 | 0.78 | RYR2 (0.64) | RYR2KCNH2 | |
| SCHEMBL19865369 | 0.78 | RYR2 (0.63) | RYR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618282-B2 | Process for preparing benzothiazepines from gamma-aminoalkylbenzenes | LES LABORATOIRES SERVIER (FR) | 2013-12-31 | — | — | US | claimed |
| EP-2250159-B1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | ARMGO PHARMA INC (US) | 2011-12-07 | — | — | EP | claimed |
| EP-2250159-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | Armgo Pharma, Inc. (US) | 2010-11-17 | — | — | EP | claimed |
| WO-2009111463-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | ARMGO PHARMA, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-20090227788-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | RYCARMA THERAPEUTICS, INC. | 2009-09-10 | — | — | US | claimed |
| US-20250302847-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYCARMA THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| US-20250170144-A1 | CRYSTALLINE FORMS OF A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYCARMA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250099483-A1 | THERAPEUTIC COMPOUNDS | RYCARMA THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| US-12161650-B2 | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof | ARMGO PHARMA, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| EP-4433062-A1 | THERAPEUTIC COMPOUNDS | Armgo Pharma, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| US-12076326-B2 | Crystalline forms of a ryanodine receptor modulator and uses thereof | ARMGO PHARMA, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-12076327-B2 | Crystalline forms of a ryanodine receptor modulator and uses thereof | ARMGO PHARMA, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20050186640-A1 | Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RYR2) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-25 | — | — | US | disclosed |
| WO-2005037195-A2 | COMPOUNDS AND METHODS FOR TREATING AND PREVENTING EXERCISE-INDUCED CARDIAC ARRHYTHMIAS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OFNEW YORK (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20040229781-A1 | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2004-11-18 | — | — | US | disclosed |
| US-20040229781-A1 | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2004-11-18 | — | — | US | disclosed |
| US-20040229781-A1 | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2004-11-18 | — | — | US | disclosed |
| EP-0565721-B1 | 1,4-BENZOTHIAZEPINE DERIVATIVE | KANEKO NOBORU (JP) | 1995-07-26 | — | — | EP | disclosed |
| US-5416066-A | FOR THE PREVENTION OF MYOCARDIAL INFARCTION OR INHIBITING MYOCARDIAL NECROSIS | KIRIN BREWERY CO., LTD. (JP) | 1995-05-16 | — | — | US | disclosed |
| EP-0565721-A1 | 1,4-BENZOTHIAZEPINE DERIVATIVE | KANEKO, Noboru (JP) | 1993-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302847-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYR1, RYR2, MUSK | RYR2 2/4885KCNH2 1132/4885 |
| US-20040229781-A1 | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias | RYR2, RYR1, FKBP4 | RYR2 1/4885KCNH2 108/4885 |
| US-12076326-B2 | Crystalline forms of a ryanodine receptor modulator and uses thereof | RYR1, RYR2, ATP2A1 | RYR2 2/4885KCNH2 1249/4885 |
| US-12076327-B2 | Crystalline forms of a ryanodine receptor modulator and uses thereof | RYR1, RYR2, ATP2A1 | RYR2 2/4885KCNH2 1249/4885 |
| US-20090227788-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | TPMT, SULT2A1, KCNJ2 | RYR2 547/4885KCNH2 103/4885 |
| US-12161650-B2 | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof | RYR1, RYR2, MUSK | RYR2 2/4885KCNH2 1132/4885 |
| US-20250170144-A1 | CRYSTALLINE FORMS OF A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYR1, RYR2, ATP2A1 | RYR2 2/4885KCNH2 1249/4885 |
| US-20250099483-A1 | THERAPEUTIC COMPOUNDS | SDHA, NDUFB7, COMT | RYR2 30/4885KCNH2 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.